The incidence of thyroid carcinoma has been increasing in recent years.More and more researchers have paid attention to this field and great achievements have been made year by year.The developments on gene diagnosis and molecular markers of thyroid carcinoma are reviewed in this article.

ObjectiveTo explore the clinical and pathological features of Hainan patients with thyroid carcinoma treated in Hainan Provincial People' s Hospital.Methods A total of 239 clinical cases of Hainan patients with thyroid carcinoma treated in Hainan Provincial People' s Hospital from 2006 to 2010 were retrospectively analyzed.Results The number of thyroid carcinoma cases between 2006 to 2008 was stable.But the cases in 2009 were 72.97％ higher than that in 2008.Female' s peak of onset age was 25 to 55 years and male was 20 to 55 years.The cases of Hant were 231 (96.65％) and the national minority were 8(3.35％ ).So ethnic composition ratio between cases and local population has a very significant difference (x2 =21.376,P ＜0.01 ).The eastern and western regions had 175 cases and 64 cases respectively,138 (78.86％) and 34(46.88％ ) cases from city respectively.Urban and rural ratio between eastern and western areas had a significant difference (x2 =4.420,P ＜ 0.05 ).The 239 cases were composed of 228 cases (95.4％) of papilarry thyroid carcinoma,7 cases (2.92％) of medullary thyroid carcinoma,both 2 cases (0.84％) of follicular thyroid carcinoma and anaplastic thyroid carcinoma.Conclusions The incidence of Hainan nationality patients with thyroid carcinoma treated in Hainan Provincial People' s Hospital has increased from 2006 to 2010,with younger trend and regional difference.Thyroid carcinoma has a difference in race and region.The rank of the rate of pathological type is papillary thyroid carcinoma,medullary thyroid carcinoma,follicular thyroid carcinoma,undifferentated thyroid carcinoma in order.

Objective To evaluate the efficacy and safety of combination chemotherapy with vinorelbine and cisplatin in the treatment of metastatic breast cancer resisting to anthracycline and taxane.Methods 20 patients with advanced metastatic breast cancer were given following regimen:Vinorelbine 25mg/m2 was given intraveniously in day 1 and day 8,cisplatin 75mg/m2 was given intraveniously in day 1 or 25mg/m2 was given intraveniously in day1 to day 3,repeated every 3 weeks.Evaluation of response and adverse reactions were practiced every 2 cycles.Results 20 patients were evaluable,among them,2 cases reach CR,8 cases PR,4 cases SD and 6 cases PD,with a median followup of 6 months(4 ～ 18months),16 patients survived and 4 patients died.The median time to progression and the median survival time was 5 months(3 ～ 15 months) and 8 months(4 ～ 18 months) respectively.The treatment well tolerated,The main toxicity was myelosuppression and gastrointestinal reaction with WHO grade Ⅲ～Ⅳ gastrointestinal reaction,neutropena and thrombocytopenia being in 25% 、65% and 10% .Conclusion The regimen of NP is safe and effective in treating advanced metastatic breast cancer resisting to anthracycline and taxane.In addition,it was able to improve survival rate and adverse reactions could be tolerated.

Objectives To investigate the expression and differential diagnosis value of Galectin-3 and Cyclin D1 in benign and malignant thyroid mass.Methods The expression of Galectin-3 and Cyclin D1 protein in 31 cases of nodular goiter(group A),65 cases of papillary thyroid carcinoma(PTC,group B) and 10 cases of normal thyroid tissues(group C,the control group)was detected by SP immunohistochemical method.The clinical data were analyzed.Results The expression level of Galectin-3 in group B was 83.03％ (54/65),significantly higher than that in group A(19.35％,6/31) and group C(0％).The difference of group A and group B in terms of the expression level of Galectin-3 protein had statistical significance(x2 =36.360,P ＜0.05).The expression level of Cyclin D1 protein in group B was 72.30％ (47/65),significantly higher than that in group A(12.90％,4/31)and group C(0％).The difference of group A and group B in terms of the expression level of Cyclin D1 protein had statistical significance(x2 =29.740,P ＜ 0.05).The combination detection of the positive expression of Galectin-3 and Cyclin D1 in benign and malignant thyroid mass showed that the difference between group A and group B had statistical significance(P ＜ 0.01).The expression of Galectin-3 and Cyclin D1 was positively correlated in group B(R =0.509,P ＜0.05).The positive expression rate of Cyclin D1 protein was 90％ (18/20) and 64.44％ (29/45)respectively in PTC patients with lymph node metastasis and without lymph node metastasis.The difference had statistical significance (P ＜ 0.05).Conclusions The expression of Galectin-3 and Cyclin D1 is positively correlated in PTC and the expression of the 2 proteins in PTC is higher than that in nodular goiter and normal thyroid tissues,indicating that the 2 proteins can be used as valuable markers for patients with thyroid carcinoma.Combined detection of Cyclin D1 and Galectin-3 protein in thyroid tissues is useful for the diagnosis of thyroid cancer.

Objective To evaluate the application value of DNA ploidy detection using flow cytometry method(FCM)in malignant tumor identifi?cation,so as to provide the theoretical basis for the clinical diagnosis of malignant tumors. Methods Two researchers finished the literature screen?ing independently,and all the literatures were given the secondary screening according to the inclusion and exclusion criteria. The included literature data was analyzed by Meta?DiSc 1.4,including heterogeneity test,sensitivity,specificity,diagnostic odds ratio(DOR)and summary receiver operat?ing characteristic(SROC)etc. Results Totally 12 literatures were included in the study finally,including a total of 1 340 subjects consisting of 516 cases with malignant tumor and 824 cases with benign tumor. Heterogeneity inspection results showed that the Spearman correlation coefficient of sensitivity logarithm and(1-specificity)logarithm was-0.343 and there was no threshold effect(P=0.275). DOR curves was Cochran?Q=26.49 (P=0.005 5),indicating the heterogeneity was caused by non threshold effects. Combined statistical quantity was calculated with a random effects model and the results were as followings:the sensitivity was 0.72(95%CI:0.68?0.76,I2=50.1%)and the specificity 0.84(95%CI:0.81?0.86,I2=65.5%). SROC curve drawing,DNA ploidy detection of benign and malignant tumors showed AUC=0.845 3 and Q*=0.776 8. Conclusion FCM DNA heteroploid has a high accuracy for diagnosis of malignant tumor,which can be an important supporting means for the discrimination between benign and malignant tumor.

OBJECTIVE:To investigate the effect of X-ray repair cross complementing gene(XRCC1)Arg399Gln(G→A) polymorphism on efficacy of oxaliplatin+fluorouracil chemotherapy and survival time of advanced gastric cancer patients. METH-ODS:Totally 52 cases of advanced gastric cancer were selected from Hainan Provincial People's Hospital during Jan. 2013-Jan. 2015. They were given oxaliplatin+fluorouracil chemotherapy,for 3 courses(a treatment course lasted for 3 weeks). The genotypes of patients were detected by PCR-LDR. Disease control rate and progression free survival were compared among different geno-types. RESULTS:Among 52 cases of advanced gastric cancer,there were 28 cases of XRCC1 GG genotype(53.8%),21 cases of GA genotype(40.4%),3 cases of AA genotype(5.8%),frequencies of which were all in line with Hardy-Weinberg balance(P>0.05). Disease control rates of 52 cases were 76.9%,among which disease control rate(92.9%)of GG genotype was significantly higher than that of GA+AA genotype(58.3%),with statistical significance(P<0.05). The average progression free survival of 52 cases was(7.1+1.2)months,among which progression free survival of GG genotype [(8.6±0.8)months] was significantly longer than that of GG+GA genotype [(5.9 ± 0.7)months],with statistical significance (P<0.05). CONCLUSIONS:XRCC1 polymor-phism is correlated with efficacy of oxaliplatin+fluorouracil chemotherapy and progression free survival,and XRCC1 GG genotype is more sensitive to chemotherapy drugs. XRCC1 gene can be regarded as predictive indicator for therapeutic efficacy of chemothera-py and survival.

Objective: To investigate the effects of recombinant human growth hormone (rhGH) and 5-fluorouracil(5-Fu) on human colon carcinoma LOVO cells in vitro. Methods: The LOVO cells during exponential growth stage were harvested and divided into control group,GH group, 5-Fu group and GH + 5-Fu group. According to the dose of GH, the GH group was separated into two sub-groups(50 ng/mL and 100 ng/mL) and the GH +5-Fu group was separated into two sub-groups. With different concentrations of rhGH and/or 5-Fu , the cell survive rates were analyzed by MTT assay after 24 h , 48 h and 72 h and cell cycle and proliferation index (PI) were analyzed by flow cytometry after 24 h. Results: Compared with the control group, the survive rates in 5-Fu and GH +5-Fu groups were decreased significantly (P <0. 05). The significant effects of rhGH on cell cycle kinetics were found in the cell line. Compared with the control group, percentage of S phase and proliferation index (PI) significantly increased (P <0.05)and percentage of G_0/G_1 phase decreased (P <0. 05) in GH groups. Percentages of cells of S phase and PI significantly decreased in GH + 5-Fu groups (P < 0. 05). Rate of apoptosis increased in 5-Fu and GH +5-Fu groups (P <0.05). Compared with the 5-Fu group, there were no statistically significant differences in percentages of cells of S phase and PI and rate of apoptosis between two GH+5-Fu groups(P >0. 05). Conclusion-. rhGH does not stimulate the LOVO cells proliferation in vitro, and its use is safe when combined with 5-fluorouracil.

Objective To investigate the relationship between APE1, XRCC1 gene polymorphisms and hepatocellular carcinoma(HCC) susceptibility and to explore the correlation of APE1, XRCC1 gene polymorphisms with the sensitivity to platinum-based drugs .Methods Seventy-eight HCC patients and 80 controls were selected .By PCR and RFLP , the single nucleotide polymorphism of APE1 Asp148Glu and XRCC1 Arg194Trp genes and the susceptibility of HCC or platinum drug sensitivity were analyzed.Results The Glu/Glu genotype of APE1 could increase in the risk of HCC by 7.21 times (95%CI:1.325-29.109) (P<0.05).APE1 and XRCC1 gene polymorphisms could also affect the platinum drug resistance of HCC patients.Conclusion APE1 Asp148Glu is correlated with the susceptibility to HCC .APE1 and XRCC1 genes can be considered a target for therapy to improve the sensitivity of HCC platinum drugs .

OBJECTIVETo investigate the effect of Zilongjin (ZLJ) on human androgen-dependent type of prostate cancer cell line LNCaP.

METHODSMTT assay, flow cytometry and fluorescence microscopy were used to observe the effect of ZLJ in anti-proliferation, cell cycle arresting and apoptosis induction. RT-PCR was used to examine the effect of ZLJ on expressions of prostate marker gene (PSA), androgen receptor (AR), apoptosis related genes (bcl-2 and bax), and Western blot assay was used to detect the effect on protein expression of bcl-2 and bax.

RESULTSZLJ could cause apparent inhibition on proliferation, induce G0/G1 phase arresting and apoptosis in time- and dose-dependent manner on LNCaP cells. The concentration for inhibiting cell growth by 50% (IC50) in 72 hrs was 0.79 mg/ml. ZLJ could down-regulate the expression of PSA, AR, bcl-2 genes and lower bcl-2 protein expression, but showed ineffective on bax protein expression.

CONCLUSIONZLJ displays its anti-tumor effects by way of inhibiting the cell proliferation, arresting the G0/G1 phase, inducing apoptosis, down-regulating PSA, AR, bcl-2 gene expression and lowering bcl-2 protein expressions.

Antineoplastic Agents, Phytogenic ; pharmacology ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Drugs, Chinese Herbal ; pharmacology ; Humans ; Male ; Neoplasms, Hormone-Dependent ; metabolism ; pathology ; Prostate-Specific Antigen ; biosynthesis ; genetics ; Prostatic Neoplasms ; metabolism ; pathology ; Proto-Oncogene Proteins c-bcl-2 ; biosynthesis ; genetics ; Receptors, Androgen ; biosynthesis ; genetics